MesenCult™-SF Attachment Substrate

Serum-free attachment substrate for human mesenchymal stem cells
MesenCult™-SF Attachment Substrate

Serum-free attachment substrate for human mesenchymal stem cells

5 mg
Catalog # 05424
377 USD
Required Products
  1. D-PBS Without Ca++ and Mg++
    D-PBS (Without Ca++ and Mg++)

    Dulbecco’s phosphate-buffered saline without calcium and magnesium

Overview

MesenCult™-SF Attachment Substrate is a serum-free substrate for the in vitro culture of human mesenchymal stem and progenitor cells (MSCs). The substrate supports both expansion of human MSCs in vitro as well as their enumeration using the colony forming unit–fibroblast (CFU-F) assay.
Cell Type
Mesenchymal Stem and Progenitor Cells
Species
Human
Brand
MesenCult

Scientific Resources

Product Documentation

Document Type Product Name Catalog # Lot # Language
Document Type
Product Information Sheet
Product Name
MesenCult™-SF Attachment Substrate
Catalog #
05424
Lot #
All
Language
English
Document Type
Safety Data Sheet
Product Name
MesenCult™-SF Attachment Substrate
Catalog #
05424
Lot #
All
Language
English

Educational Materials (4)

Brochure
Products for Your Mesenchymal Stromal Cell Research
Video
Isolation of Umbilical Cord Mesenchymal Stromal Cells Using Explant Method
13:45
Isolation of Umbilical Cord Mesenchymal Stromal Cells Using Explant Method
Webinar
The Impact of Ancillary Materials on Your Translational Research
17:18
The Impact of Ancillary Materials on Your Translational Research
Mini Review
Mesenchymal Stromal Cells: Markers, Isolation and Culture, Differentiation, and Therapeutic Potential

Product Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Data and Publications

Publications (1)

Frontiers in immunology 2019 Pneumococcal Polysaccharide Vaccine Ameliorates Murine Lupus. C. Cantarelli et al.

Abstract

Current guidelines encourage administering pneumococcal vaccine Prevnar-13 to patients with lupus, but whether such vaccinations affect disease severity is unclear. To address this issue, we treated 3-month-old MRL-lpr mice, that spontaneously develop a lupus-like syndrome, with Prevnar-13 or vehicle control. After 3 months, we quantified circulating anti-Pneumococcal polysaccharide capsule (PPS) antibodies and signs of disease severity, including albuminuria, renal histology and skin severity score. We also compared immunophenotypes and function of T and B cells from treated and untreated animals. Prevnar-13 elicited the formation of anti-pneumococcal IgM and IgG. Prevnar-13 treated animals showed reduced albuminuria, renal histological lesions, and milder dermatitis compared to vehicle-treated controls. Mitigated disease severity was associated with reduced and increased T follicular helper cells (TFH) and T follicular regulatory cells (TFR), respectively, in Prevnar-treated animals. T cells from Prevnar-13 vaccinated mice showed differential cytokine production after aCD3/aCD28 stimulation, with significantly decreased IL-17 and IL-4, and increased IL-10 production compared to non-vaccinated mice. In conclusion, pneumococcal vaccination elicits anti-pneumococcal antibody response and ameliorates disease severity in MRL-lpr mice, which associates with fewer TFH and increased TFR. Together, the data support use of Prevnar vaccination in individuals with SLE.
View All Publications

Contact STEMCELL Technologies

Our Customer Service, Sales, and Product and Scientific Support departments in North America are available between 6 am and 5 pm Pacific Time (9 am and 8 pm Eastern Time). One of our representatives will be happy to help you by telephone or email. Please complete the form to contact us by email. A representative will get back to you shortly.
  •  

StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not share your email address with third parties. StemCell Technologies Inc. will use your email address to confirm your identity and send you newsletters, transaction-related emails, promotional and customer service emails in accordance with our privacy policy. You can change your email preferences at any time.